ArticleBiology direct2026
S100A4 triggeres the pyroptosis of vsmcs: association with mitochondrial damage, impaired mitophagy, and Ca
Article in Biology direct, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundAtherosclerotic occlusive disease of the lower extremities (ASO-LE) is associated with high rates of disability and mortality, and even after surgery, the rate of long-term lumen patency remains low. Vascular smooth muscle cells (VSMCs) are key players in atherosclerosis. The aim of this study was to investigate the action of S100 calcium-binding protein A4 (S100A4) in regulating VSMCs in ASO-LE.
resultsThe overexpression of S100A4 in the vessel wall of ASO-LE is detected, and the expression of markers of pyroptosis is high. S100A4 causes mitochondrial damage in VSMCs, increases the intracellular ROS and MDA levels, and decreases the level of SOD, which result in oxidative stress. Moreover, S100A4 disrupts the mitophagy process, manifested by inhibited LC3-II conversion and reduced PE levels, suggesting that the lipidation step of LC3 may be disrupted. These promot the accumulation of a large amount of damaged mitochondria with insufficient clearance and activate intracellular AIM2 inflammatory vesicles, which mediate the occurrence of pyroptosis. We also find that the functions of S100A4 may be associated with disturbances in intracellular calcium ion (Ca2+) signaling, both S100A4 transcription inhibitor (niclosamide) and calcium channel blockers can inhibit the above damaging effects.
conclusionsS100A4 plays a crucial role in the progression of ASO-LE by driving mitochondrial damage and impairing mitophagy in vascular smooth muscle cells, and it is a potential existing strategies for blocking chronic inflammation that may be used to treat lower extremity atherosclerotic occlusion. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.